Cite

HARVARD Citation

    Gonçalves, J. et al. (n.d.). P664 SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis. Journal of Crohn's and colitis. pp. S451-S452. [Online]. 
  
Back to record